These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 16791802

  • 41. SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma.
    Fu L, Li H, Wang H, Xu B, Fan Y, Tian J.
    PLoS One; 2012; 7(12):e50914. PubMed ID: 23226547
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY, Kao A, Yen RF.
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [Abstract] [Full Text] [Related]

  • 45. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
    Zhang Q, Tian T, Wang L, Qiu H, Li D.
    Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
    [Abstract] [Full Text] [Related]

  • 46. [Value of endosonography in diagnostic staging of primary gastric lymphoma (MALT type)].
    Hoepffner N, Lahme T, Gilly J, Menzel J, Koch P, Foerster EC.
    Med Klin (Munich); 2003 Jun 15; 98(6):313-7. PubMed ID: 12811415
    [Abstract] [Full Text] [Related]

  • 47. Role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating breast mucosa-associated lymphoid tissue lymphoma: A case series.
    Albano D, Bosio G, Orlando E, Bertagna F.
    Hematol Oncol; 2017 Dec 15; 35(4):884-889. PubMed ID: 28004400
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, Dhurairaj T, Dadparvar S, Alavi A.
    J Nucl Med; 2004 Nov 15; 45(11):1796-803. PubMed ID: 15534046
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. 18F-FDG PET/CT or PET Role in MALT Lymphoma: An Open Issue not Yet Solved-A Critical Review.
    Albano D, Durmo R, Treglia G, Giubbini R, Bertagna F.
    Clin Lymphoma Myeloma Leuk; 2020 Mar 15; 20(3):137-146. PubMed ID: 32029397
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma.
    Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz Vicente F, Borrego-Dorado I, Ruiz Mercado M, Acevedo Báñez I, Solé Rodríguez M, Fernández López R, Pérez Vega H, Calderón-Cabrera C, Espigado Tocino I, Pérez-Simón JA, Vázquez-Albertino R.
    Hematol Oncol; 2015 Dec 15; 33(4):151-8. PubMed ID: 25407794
    [Abstract] [Full Text] [Related]

  • 54. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Haematologica; 2000 Jun 15; 85(6):613-8. PubMed ID: 10870118
    [Abstract] [Full Text] [Related]

  • 55. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Ann Oncol; 2002 Sep 15; 13(9):1356-63. PubMed ID: 12196360
    [Abstract] [Full Text] [Related]

  • 56. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ.
    J Nucl Med; 2002 Aug 15; 43(8):1018-27. PubMed ID: 12163626
    [Abstract] [Full Text] [Related]

  • 57. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up.
    Raderer M, Wöhrer S, Kiesewetter B, Dolak W, Lagler H, Wotherspoon A, Muellauer L, Chott A.
    Ann Hematol; 2015 Jun 15; 94(6):969-73. PubMed ID: 25579756
    [Abstract] [Full Text] [Related]

  • 58. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J, Qiao W, Wang C, Wang T, Xing Y.
    Hematology; 2007 Oct 15; 12(5):423-30. PubMed ID: 17852456
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. [Prognostic impact of Helicobacter pylori infection and eradication therapy in gastric mucosa-associated lymphoid tissue lymphoma].
    Park SH, Chi HS, Park SJ, Jang S, Park CJ, Huh JR.
    Korean J Lab Med; 2010 Dec 15; 30(6):547-53. PubMed ID: 21157137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.